Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
英矽智能与齐鲁制药达成最新交易：一项价值1.2亿美元的心代谢疾病药物研发合作

Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly $120 million.
英矽智能可谓风头正劲。继与赛威和Hygtia Therapeutics达成协议后，这家生物科技公司又与总部位于上海的齐鲁制药签下了一笔接近1.2亿美元的新合作。